MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype

Viewpoint summarises the data and implications of the MILO study investigating the use of binimetinib in low-grade serous ovarian cancer. It states that although not meeting its primary end point, disease control occurred in a significant number of patients.


Journal of Clinical Oncology